Citations

Institution: Mayo Clinic Clear

Showing 10 of 108135 citations.

Response to Implementation of Rapid Cortisol During Adrenal Vein Sampling
Auchus, Richard J. , Lenders, Jacques W.M. , Plouin, P.-F., Satoh, Fumitoshi , Rossi, Gian Paolo , Brown, Morris Jonathan , Naruse, Mitsuhide , Young, William F. , Rossi, Gian Paolo

Hypertension | February 25, 2014 | Volume: 63 | Issue: 4 | Pages: No page available

10.1161/hypertensionaha.114.03091 | PMID 24757726 Get It

Response to Letter Regarding Article, “Quantification of Incomplete Revascularization and Its Association With Five-Year Mortality in the Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery (SYNTAX) Trial: Validation of the Re
Farooq, Vasim , Bourantas, Christos V. , Zhang, Yao‐Jun , Muramatsu, Takashi , Feldman, Ted , Holmes, David R. , Mack, Michael J. , Morice, Marie Claude, Ståhle, Elisabeth , Colombo, Antonio , Vries, Ton de, Morel, Marie-angèle , Dawkins, Keith D., Mohr, Friedrich W., Serruys, Patrick W. , Morice, Marie‐Claude, Kappetein, A. Pieter

Circulation | February 24, 2014 | Volume: 129 | Issue: 8 | Pages: No page available

10.1161/circulationaha.114.008026 | PMID 24566072 Get It

Long‐term follow‐up of a phase 2 trial of single agent lenalidomide in previously untreated patients with chronic lymphocytic leukaemia
Chen, Christine I. , Paul, Harminder, Wang, Trina, Le, Lisa W. , Dave, Nimisha, Kukreti, Vishal , Wei, Ellen, Lau, Anthea , Bergsagel, P. Leif , Trudel, Suzanne , Bergsagel, P. Leif

British Journal of Haematology | February 24, 2014 | Volume: 165 | Issue: 5 | Pages: 731-733

10.1111/bjh.12785 | PMID 24611934 Get It

Non‐invasive isometric force measurement of plantar flexors in rats
Chawla, Aditya , Spinner, Robert J. , Lizardi, Michael Torres , Yaszemski, Michael J. , Windebank, Anthony J. , Wang, Huan

Muscle & Nerve | February 24, 2014 | Volume: 50 | Issue: 5 | Pages: 812-821

10.1002/mus.24219 | PMID 24639363 Get It

ABSTRACTIntroduction: Isometric muscle force measurement is a sensitive marker for motor function recovery in rat nerve repair models. Current methods of eliciting maximal isometric force with nerve stimulation cannot provide longitudinal data.Methods: We developed a novel method for measuring isometric muscle force with a device designed to allow minimally invasive nerve stimulation and measurement of plantar flexion force. This indirectly elicited muscle force was compared with muscle force elicited by direct muscle stimulation in 3 surgical models.Results: The force measured after sciatic nerve transection and repair followed a parabolic trend. There was a postinjury decrease in force that continued until postoperative day 42, after which the force increased with time, indicating muscle reinnervation.Conclusions: This approach can track longitudinal changes in force in the most common animal model for studies of clinically relevant problems in the peripheral nerve field.Muscle Nerve50: 812–821, 2014
Excellent local control with preoperative radiation therapy, surgical resection, and intra‐operative electron radiation therapy for retroperitoneal sarcoma
Stucky, Chee‐Chee H., Wasif, Nabil , Ashman, Jonathan B. , Pockaj, Barbara A. , Gunderson, Leonard L., Gray, Richard J.

Journal of Surgical Oncology | February 24, 2014 | Volume: 109 | Issue: 8 | Pages: 798-803

10.1002/jso.23576 | PMID 24862926 Get It

PurposeTo examine the value of surgical resection combined with preoperative external beam radiation therapy and intraoperative radiation therapy (Surg‐RT) for retroperitoneal sarcoma (RPS).MethodsReview of 63 consecutive patients with RPS from 1996 to 2011.ResultsThirty‐seven patients (59%) underwent Surg‐RT and 26 (41%) had surgery alone. 51% of tumors were high grade and 36% of patients had locally recurrent disease. Final margin status was: R0 73%, R1 16%, R2 6%, and unknown 5%. Of those with R0 resections, 67% received Surg‐RT. Median follow‐up was 45 months. The 5‐year local control rate was 89% for Surg‐RT patients and 46% for surgery alone patients (P = 0.03). On multivariate analysis, Surg‐RT was the only variable associated with a lower risk of LR (HR 0.19; CI 0.05–0.69, P = 0.003). The actuarial 5‐year OS was 60% for patients receiving either Surg‐RT or surgery alone.ConclusionsThe combination of pre‐operative radiation, surgical resection, and intraoperative radiation produces excellent local disease control for RPS. Combination therapy was associated with improved local control but not with overall survival. J. Surg. Oncol. 2014 109:798–803. © 2014 Wiley Periodicals, Inc.
Core Binding Factor β (CBFβ) Is Retained in the Midbody During Cytokinesis
López‐Camacho, César , Wijnen, André J. van , Lian, Jane B. , Stein, Janet L. , Stein, Gary S. , van Wijnen, Andre J

Journal of Cellular Physiology | February 24, 2014 | Volume: 229 | Issue: 10 | Pages: 1466-1474

10.1002/jcp.24588 | PMID 24648201 Get It

AbstractCore Binding Factor β (CBFβ) is complexed with the RUNX family of transcription factors in the nucleus to support activation or repression of genes related to bone (RUNX2), hematopoiesis (RUNX1) and gastrointestinal (RUNX3) development. Furthermore, RUNX proteins contribute to the onset and progression of different types of cancer. Although CBFβ localizes to cytoskeletal architecture, its biological role in the cytoplasmic compartment remains to be established. Additionally, the function and localization of CBFβ during the cell cycle are important questions relevant to its biological role. Here we show that CBFβ dynamically distributes in different stages of cell division and importantly is present during telophase at the midbody, a temporal structure important for successful cytokinesis. A functional role for CBFβ localization at the midbody is supported by striking defects in cytokinesis that include polyploidy and abscission failure following siRNA‐mediated downregulation of endogenous CBFβ or overexpression of the inv(16) fusion protein CBFβ‐SMMHC. Our results suggest that CBFβ retention in the midbody during cytokinesis reflects a novel function that contributes to epigenetic control. J. Cell. Physiol. 229: 1466–1474, 2014. © 2014 Wiley Periodicals, Inc.
Faculty Opinions recommendation of Microglia promote learning-dependent synapse formation through brain-derived neurotrophic factor.
Eyo, Ukpong B , Wu, Long‐Jun , Eyo, Ukpong B.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | February 24, 2014 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.718215513.793491233 Get It

A Novel DCTN1 mutation with late‐onset parkinsonism and frontotemporal atrophy
Tsuboi, Yoshio , Daechsel, Justus, Milnerwood, Austen J. , Vilariño‐Güell, Carles , Fujii, Naoki, Mishima, Takayasu , Oka, Takayuki , Hara, Hideo , Fukae, Jiro, Farrer, Matthew J. , Araki, Eiichi

Movement Disorders | February 24, 2014 | Volume: 29 | Issue: 9 | Pages: 1201-1204

10.1002/mds.25833 | PMID 24676999 Get It

ABSTRACT Background Depression, parkinsonism, and hypoventilation (Perry syndrome) or familial motor neuron disease have been linked to mutations in dynactin P150 Glued ( DCTN1 ). Methods We employed genealogic, clinical, neurologic, and MRI investigations, as well as analysis of genes implicated in parkinsonism. Cellular transfection, immunocytochemistry, and immunoprecipitation analysis of wild‐type (WT) and mutant DCTN1 were also performed. Results A novel heterozygous mutation, DCTN1 c.156T>G, encoding p.Phe52Leu, segregates with parkinsonism in a Japanese family. The substitution was not observed in affected probands with familial parkinsonism or control subjects and is evolutionarily conserved. In contrast to Perry syndrome, affected carriers have late‐onset disease and slower progression, with frontotemporal atrophy revealed by MRI. In vitro studies suggest the mutant protein has impaired microtubule binding, compared to WT dynactin p150 Glued . Conclusions DCTN1 mutations may contribute to disparate neurodegenerative diagnoses, including familial motor neuron disease, parkinsonism, and frontotemporal atrophy, and further studies of dynactin‐mediated cargo transport may prove insightful. © 2014 International Parkinson and Movement Disorder Society
Two‐year seizure reduction in adults with medically intractable partial onset epilepsy treated with responsive neurostimulation: Final results of the RNS System Pivotal trial
Heck, Christianne, King‐Stephens, David , Nair, Dileep , Jobst, Barbara C. , Barkley, Gregory L., Salanova, Vicenta , Gwinn, Ryder P. , Skidmore, Christopher , Ness, Paul C. Van, Bergey, Gregory K. , Park, Yong D., Miller, Ian , Geller, Eric B., Rutecki, Paul , Zimmerman, Richard S. , Spencer, David , Leiphart, James W., Wharen, Robert E. , Fessler, James, Fountain, Nathan B. , Eisenschenk, Stephan, Duckrow, Robert B., Hirsch, Lawrence J. , Bazil, Carl W., O’Donovan, Cormac A. , Sun, Felice T., Courtney, Tracy A., Seale, Cairn G. , Morrell, Martha J. , Massey, Andrew D. , Cole, Andrew J. , Smith, Michael C. F. , Goldman, Alica M. , Edwards, Jonathan , Worrell, Gregory A. , Gross, Robert E. , Fountain, Nathan , Hirsch, Lawrence J , Jobst, Barbara , Nair, Dileep R , Skidmore, Christopher , Morrell, Martha J

Epilepsia | February 24, 2014 | Volume: 55 | Issue: 3 | Pages: 432-441

10.1111/epi.12534 | PMID 24621228 Get It

Summary Objective To demonstrate the safety and effectiveness of responsive stimulation at the seizure focus as an adjunctive therapy to reduce the frequency of seizures in adults with medically intractable partial onset seizures arising from one or two seizure foci. Methods Randomized multicenter double‐blinded controlled trial of responsive focal cortical stimulation (RNS System). Subjects with medically intractable partial onset seizures from one or two foci were implanted, and 1 month postimplant were randomized 1:1 to active or sham stimulation. After the fifth postimplant month, all subjects received responsive stimulation in an open label period ( OLP ) to complete 2 years of postimplant follow‐up. Results All 191 subjects were randomized. The percent change in seizures at the end of the blinded period was −37.9% in the active and −17.3% in the sham stimulation group (p = 0.012, Generalized Estimating Equations). The median percent reduction in seizures in the OLP was 44% at 1 year and 53% at 2 years, which represents a progressive and significant improvement with time (p < 0.0001). The serious adverse event rate was not different between subjects receiving active and sham stimulation. Adverse events were consistent with the known risks of an implanted medical device, seizures, and of other epilepsy treatments. There were no adverse effects on neuropsychological function or mood. Significance Responsive stimulation to the seizure focus reduced the frequency of partial‐onset seizures acutely, showed improving seizure reduction over time, was well tolerated, and was acceptably safe. The RNS System provides an additional treatment option for patients with medically intractable partial‐onset seizures.
The RAZOR (randomized open vs robotic cystectomy) trial: study design and trial update
Smith, Norm D. , Castle, Erik P., Gonzalgo, Mark L. , Svatek, Robert S. , Weizer, Alon Z. , Montgomery, Jeffrey S., Pruthi, Raj S. , Tollefson, Matthew K. , Konety, Badrinath R. , Shabsigh, Ahmad , Krupski, Tracey L. , Barocas, Daniel A. , Dash, Atreya , Kibel, Adam S. , Parekh, Dipen J. , Woods, Michael E. , Quek, Marcus Lee

BJU International | February 24, 2014 | Volume: 115 | Issue: 2 | Pages: 198-205

10.1111/bju.12699 | PMID 25626182 Get It

The purpose of the RAZOR (randomized open vs robotic cystectomy) study is to compare open radical cystectomy ( ORC ) vs robot‐assisted RC ( RARC ), pelvic lymph node dissection ( PLND ) and urinary diversion for oncological outcomes, complications and health‐related quality of life ( HRQL ) measures with a primary endpoint of 2‐year progression‐free survival ( PFS ). RAZOR is a multi‐institutional, randomized, non‐inferior, phase III trial that will enrol at least 320 patients with T 1– T 4, N 0– N 1, M 0 bladder cancer with ≈160 patients in both the RARC and ORC arms at 15 participating institutions. Data will be collected prospectively at each institution for cancer outcomes, complications of surgery and HRQL measures, and then submitted to trial data management services Cancer Research and Biostatistics ( CRAB ) for final analyses. To date, 306 patients have been randomized and accrual to the RAZOR trial is expected to conclude in 2014. In this study, we report the RAZOR trial experimental design, objectives, data safety, and monitoring, and accrual update. The RAZOR trial is a landmark study in urological oncology, randomizing T 1– T 4, N 0– N 1, M 0 patients with bladder cancer to ORC vs RARC , PLND and urinary diversion. RAZOR is a multi‐institutional, non‐inferiority trial evaluating cancer outcomes, surgical complications and HRQL measures of ORC vs RARC with a primary endpoint of 2‐year PFS . Full data from the RAZOR trial are not expected until 2016–2017.